Description: 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Home Page: www.60degreespharma.com
1025 Connecticut Avenue NW
Washington,
DC
20036
United States
Phone:
202-327-5422
Officers
| Name | Title |
|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, CEO & President |
| Mr. Tyrone Miller | CFO & Treasurer |
| Dr. Bryan Smith | Chief Medical Officer |
| Ms. Kristen Landon | Chief Commercial Officer |
| Ms. Jennifer Herz | Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 11.5067 |
| IPO Date: | 2023-07-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |